Utah-based AI biotech company Recursion Pharmaceuticals has announced a public offering of around 30.7 million of its Class A common shares at USD 6.50 per share.
The company also granted underwriters a 30-day option to purchase an additional 4.6 million common shares. The offering, which is expected to close on or about June 28, 2024, is expected to raise an overall gross proceeds of USD 200 million.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.